Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8384755 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL9544732 | 0.89 | CA12 (0.55) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL8908339 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL5772033 | 0.86 | CA1 (0.52) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL3667908 | 0.86 | CA1 (0.52) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL8478378 | 0.84 | ALDH1A1 (0.50) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL8478375 | 0.84 | ALDH1A1 (0.50) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL19731338 | 0.84 | CA12 (0.50) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL104703 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL30945155 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449168-B2 | Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors | THE UNIVERSITY OF TOLEDO (US) | 2019-10-22 | — | — | US | claimed |
| US-20180250252-A1 | POTENT PHTHALATE INHIBITORS OF ASPARTATE N-ACETYLTRANSFERASE AND SELECTIVE ASPARTATE PATHWAY INHIBITORS | THE UNIVERSITY OF TOLEDO (US) | 2018-09-06 | — | — | US | claimed |
| WO-2017040376-A1 | POTENT PHTHALATE INHIBITORS OF ASPARTATE N-ACETYLTRANSFERASE AND SELECTIVE ASPARTATE PATHWAY INHIBITORS | THE UNIVERSITY OF TOLEDO (US) | 2017-03-09 | — | — | WO | claimed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110981715-B | Protein chemical cross-linking agent and preparation method and application thereof | 北京大学 | 2021-08-10 | — | — | CN | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| CN-110981715-A | Protein chemical cross-linking agent and preparation method and application thereof | 北京大学 | 2020-04-10 | — | — | CN | disclosed |
| US-10449168-B2 | Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors | THE UNIVERSITY OF TOLEDO (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2008033567-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| EP-0936218-B1 | BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6387938-B1 | Benzimidazole derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-0936218-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449168-B2 | Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors | NAT1, SAT1, NAALAD2 | ALDH1A1 104/4885LMNA 3903/4885CA1 451/4885 |
| US-20180250252-A1 | POTENT PHTHALATE INHIBITORS OF ASPARTATE N-ACETYLTRANSFERASE AND SELECTIVE ASPARTATE PATHWAY INHIBITORS | NAT1, SAT1, NAALAD2 | ALDH1A1 104/4885LMNA 3903/4885CA1 451/4885 |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | MAP3K20, MAP3K3, MAP3K19 | ALDH1A1 2086/4885LMNA 2890/4885CA1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.